ArticleIn vivo (Athens, Greece)
The Prognostic Role of Baseline and Early Dynamics of Peripheral Blood Cell Ratios in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia.Frontiers in immunology · 2026Article
- A predictive model for immunotherapy efficacy in cancer based on dynamic changes of CD8+ T cells: a pan-cancer retrospective study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimImmune checkpoint inhibitors (ICI), including nivolumab, have become the cornerstone of systemic treatment in metastatic renal cell carcinoma (mRCC). Blood-derived biomarkers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) have emerged as important indicators of systemic inflammatory and immune status. The aim of this study was to evaluate the prognostic and predictive value of NLR, PLR, and LMR at baseline and their early dynamics during nivolumab monotherapy in mRCC patients. PATIENTS AND
methodsThe associations of baseline NLR, PLR, LMR and their changes (Δ) after one month of nivolumab therapy with patient outcomes including progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) were retrospectively analyzed.
resultsIn total, 310 patients were included. Baseline NLR ≥4 (PFS: HR=2.136,
conclusionThe results of the present study suggest a prognostic role for baseline NLR, PLR and LMR. In addition, an early change in NLR and PLR is associated with patient outcome and represents a candidate surrogate biomarker for monitoring the immunotherapy response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.